KB-1311

Tezepelumab

52702

Home » Tezepelumab

Background of Tezepelumab

Tezepelumab, marketed as Tezspire, is a human monoclonal antibody designed for the treatment of asthma. It functions by inhibiting thymic stromal lymphopoietin (TSLP), an epithelial cytokine that plays a pivotal role in the onset and maintenance of airway inflammation. Tezepelumab targets TSLP, which is released in response to various triggers such as allergens and viral infections. By blocking TSLP, Tezepelumab helps prevent the activation of inflammatory pathways that contribute to asthma exacerbations. This mechanism is significant as TSLP is implicated in diverse forms of airway inflammation, including both allergic and non-allergic asthma phenotypes.

Specifications

Catalog Number	KB-1311
Antibody Name	Tezepelumab
Isotype	Human IgG2, lambda
FC Muations	S378A
Target	TSLP
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Verstraete K, Peelman F, Braun H, Lopez J, Van Rompaey D, Dansercoer A, et al. (April 2017). "Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma". Nature Communications. 8 (1): 14937. Bibcode:2017NatCo...814937V.
"Tezspire Product information". Health Canada. 25 April 2012. Archived from the original on 1 October 2022. Retrieved 1 October 2022.